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Background: Recruiting minorities into research studies requires special attention, particularly when studies involve
“extra-vulnerable” participants with multiple vulnerabilities, e.g., pregnant women, the fetuses/neonates of ethnic
minorities, children in refugee camps, or cross-border migrants. This study retrospectively analyzed submissions to the
Ethics Committee of the Faculty of Tropical Medicine (FTM-EC) in Thailand. Issues related to the process and outcomes of
proposal review, and the main issues for which clarification/revision were requested on studies, are discussed extensively.
Methods: The study data were extracted from proposals and amendments submitted to the FTM-EC during the period
October 2009 – September 2012, and then analyzed qualitatively and quantitatively. The main issues for clarification/
revision were analyzed by thematic content analysis.
Results: 373 proposals were submitted; 44 studies involved minority groups with 21 extra-vulnerable minorities.
All clinical and 2/3 of non-clinical studies submitted for initial review underwent full-board review. For combined clinical
and non-clinical study submissions, 92.1% were referred back to the investigators and approved after clarification/revision,
while 2.7% were deferred due to major/critical changes, and 2.1% not approved due to substantial violations of ethical
principles. The main issues needing clarification/revision differed between all studies and those involving minorities:
participant information sheet (62.2% vs. 86.4%), informed consent/assent form (51.2% vs. 86.4%), and research
methodology (80.7% vs. 84.1%), respectively. The main ethical issues arising during the meetings, regarding studies
involving minorities, included ensuring no exploitation, coercion, or pressure on the minority to participate; methodology
not affecting their legal status; considering ethnicity and cultural structure; and providing appropriate compensation.
Conclusion: Delays in the approval or non-approval of studies involving minorities were mainly due to major or minor
deviations from acceptable ethical standards and/or unclear research methodology. The FTM-EC has employed several
mechanisms in its operations, including transparency in the review process, building good relationships via open
communication with investigators, requesting investigators to consider closely the necessity to enroll minority groups
and the risk-benefits for individuals and their communities, and the inclusion of minority-community engagement
when developing the proposal. Other effective activities include annual study-site inspections, and offering refresher
courses to raise awareness of minority and vulnerability issues among researchers.
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Institutional review boards (IRBs) typically apply com-
mon rules and regulations to protect human research
subjects, in accordance with Title 45 § 46 of the US
Code of Federal Regulations (45 C.F.R. § 46) regarding
informed consent process, balance of risks and benefits,
protection of participant privacy, and other requirements
for the approval of proposed research. Additional sub-
parts of 45 C.F.R. § 46 are also usually enforced for the
specific protection of certain vulnerable populations, in-
cluding pregnant women, fetuses, and neonates (Subpart
B); prisoners (Subpart C); and children (Subpart D) [1].
According to the Council for International Organi-
zations of Medical Sciences (CIOMS) guidelines of 2002,
vulnerable research participants should receive special
attention, as they may suffer from stigmatization, have
limited power, lower educational levels, poverty, limited
resources, inadequate physical strength and/or other
necessary attributes to protect and defend their own in-
terests [2]. IRBs thus play major roles in safeguarding
against the potential coercion, inducement, and exploit-
ation of these particularly vulnerable groups [3-5].
For project proposals, the most common set of secular
principles employed by IRBs include respect for auton-
omy, non-maleficence, beneficence, and justice [2]. A key
responsibility of IRBs is to balance moral and humane
principles with the likelihood of gaining new knowledge
from the conduct of research involving humans, which
could benefit society in general. However, in attempting to
safeguard ethical standards, IRBs have obligations to all
stakeholders. They have obligations to ensure and protect
the rights of study participants, to the society that provides
the resources for research, and to researchers, and the ob-
ligation to treat their proposals with just consideration
and respect [6]. The management of these principles,
roles, and obligations can be highly complex, and conflict
may arise since they are not necessarily complementary or
mutually exclusive. It may be especially sensitive when re-
search studies involve more vulnerable populations. Spe-
cial attention is usually required when study populations
are incompetent persons, women (pregnant or not), chil-
dren, prisoners, refugees, other socio-economically disad-
vantaged groups, and ethnic minority groups [4,5,7]. It
becomes even more complex, usually requiring extensive
discussion among IRB members, when studies involve
participants with multiple vulnerabilities, described herein
as “extra-vulnerable” populations, e.g., pregnant women
or the fetuses/neonates of ethnic minorities, children
inhabiting refugee camps, or illegal cross-border migrants.
This study retrospectively analyzed all study applica-
tions submitted to an IRB, namely the Ethics Committee
of the Faculty of Tropical Medicine (FTM-EC), Mahidol
University, Thailand. The FTM-EC adopts and complies
with international standards in the review of protocolsinvolving human research participants; its review process
includes individual consideration and group discussion of
the relevant issues. Discussion before reaching consensus
ensures that the basic rights of human-research subjects
are protected. Corresponding to the standard ICH and
CIOMS guidelines [2,8] and the specific ethical guidelines
proposed for minority populations [7,9,10], the FTM-EC
members consider the core ethical principles, as follows:
(a) do no harm to the individual, (b) respect the privacy of
participants; (c) maintain the confidential information and
anonymity of participants (which is becoming critical, es-
pecially when a study employs peer groups and inter-
preters in minority ethnic communities), and (d) assure an
appropriate informed-consent process (with special atten-
tion to the literal translation of the “Participant Informa-
tion Sheet” in the language understood and preferred by
minority ethnic participants).
The FTM-EC has extensive experience of studies in-
volving vulnerable and extra-vulnerable populations in
Thailand. Besides core ethical principles, special con-
cerns about exploiting vulnerable and extra-vulnerable
study participants have routinely and extensively been
expressed by FTM-EC members. According to the
CIOMS guidelines [2], any study requiring the recruit-
ment of vulnerable research subjects must strictly apply
“special justification”, such that: (a) it is scientifically ne-
cessary to conduct the study with a vulnerable subject
group; (b) the study is intended to obtain knowledge and
assurance that the results could improve diagnosis, pre-
vention or treatment for the vulnerable group; and (c)
the risks for the vulnerable group would not exceed
those for other groups.
The main objective of this study was to review and
analyze the FTM-EC research proposal review process
and outcomes, with particular attention to minority pop-
ulations. Other studies exploring the ethical review
process suggested that study investigators were typically
requested to clarify the proposal’s informed consent
process; other issues included failure to comply with
good clinical practice, lack of adequate information, and
discrepancies in the information provided [11,12]. This
study also examined the main issues for which clarifica-
tion/revision were requested, particularly from initial
and continuing reviews of studies involving minority
groups, and deferred or non-approved studies.
Methods
The study data were collected from all proposals and
amendments submitted to the FTM-EC for initial and
continuing review during the period October 2009 –
September 2012. FTM-EC has been functioning since
1993 and it is one of ten IRBs officially recognized by the
Food and Drug Administration (FDA) of Thailand. Since
2009, two Ethics Committee panels have been formed:
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views non-clinical trials. The functions of the two panels
differ in terms of proposal review. Panel 1 is composed
of 18 members, 9 physicians, 7 non-physicians (medical
technology, research nurses, statisticians, lawyer, re-
search management/operational staff ) and 3 laypersons;
this panel reviews protocols that are classified as clinical
trials/ research. Panel 2, composed of 13 members, 3
physicians, 8 non-physicians and 3 laypersons (the law-
yer also acts as a lay person), reviews all non-clinical
research, including biomedical science (for both labora-
tory and field studies), social science, observational and
epidemiological research, and postgraduate-student re-
search studies. Both panels perform under the same
standard operating procedures (SOPs) in their monthly
review of research proposals.
Panel 1 convenes during week 1, and Panel 2 during
week 2 of each month. They review both initial and con-
tinuing studies. “Initial review” refers to the first submis-
sion of a protocol to the FTM-EC for review, whereas
“continuing review” includes studies where the amend-
ment of a protocol or continual annual approval has
been requested. Continuing review requires full-board re-
view when the protocol amendment includes major issues,
e.g., changes in sample size, drug dosage, or amount of
blood drawn. Regarding the request for annual approval
review, researchers are required to report study progress
and any serious incidents occurring during the conduct of
the study for FTM-EC review; thus, the primary commit-
tee members overseeing the request can detect any change
or deviation/violation from the original proposal. Annual
reviews are submitted together with amendments, if any
change(s) are proposed to the original protocol. According
to the FTM-EC guideline for researchers, “amendment” is
defined as a written description of a change(s) to or formal
clarification of a protocol. Staff of the Ethics Committee
Secretariat, Office of Research Services, Faculty of Trop-
ical Medicine, collect all comments from the (typically)
two primary reviewers, and all other Ethics Committee
members prior to the meeting, and also record all discus-
sions during the meeting. Issues raised by all reviewers are
then summarized for the investigators who submitted the
proposal. The average number of research project pro-
posals reviewed per month was 10.36 (3.86 for Panel 1
and 6.5 for Panel 2). To protect the rights and welfare of
human participants and ensure that the research projects
approved by the committee are conducted according to
the stated methodology, the FTM-EC has specified a pol-
icy of random annual site visits to selected study sites with
ongoing projects, usually one clinical and one non-clinical
study per year. According to its SOP, the Chairperson of
each panel designates Ethics Committee members res-
ponsible for collecting and recording a non-compliance in-
ventory. For the selected project, the investigators areinformed ahead of time with the details of what will be
inspected/monitored on the agreed-upon visit date. The
monitoring team prepares a checklist, reviews the neces-
sary documents (e.g., SAE and unexpected events reports)
and scopes the site visit. A field briefing meeting of the
monitoring team and the investigators is held before the
actual site visit (the briefing covers the purpose of the visit
and what is to be reviewed) and afterwards (what was ob-
served and explanations/clarifications). A formal summary
report is provided to the investigators after the monitoring
activities have been completed.
During the study period, and with permission from
the Chairpersons of both Panels 1 and 2, initial and
amended proposals are examined for type (clinical or
non-clinical) and study population (minority or other-
wise). Proposals are also categorized into studies in-
volving ethnic-minority populations, which include
displaced populations, cross-border populations, refu-
gees, and legal and illegal migrant workers in different
settings. Of the minority populations identified, “extra-
vulnerable minorities” refers to pregnant women, fe-
tuses and neonates of ethnic minority populations.
The relevant study data were extracted from docu-
ments filed at the secure FTM-EC facility, then analyzed
qualitatively and quantitatively by the research team,
who are members of the two FTM-EC panels. Summary
statistical data for the review process and outcomes were
determined according to FTM-EC guidelines. Adopting
international standards for protocol review, the FTM-EC
Chairpersons and Committee Secretary classify each
proposal into type for review, for allocation to the ap-
propriate Committee. The criteria for full-board review,
which is determined by the Chairperson, are studies that
involve more than minimal risk and involve elements,
procedures, or interventions that require additional pro-
visions or safeguards. Expedited review is potentially
available to proposals with minimal risk, which may in-
clude identifiers (direct or indirect), topics that are not
sensitive, populations that may include regulated vulner-
able populations and others with adequate protection,
and studies that require continuing IRB review. Expe-
dited review may also be granted for studies that have
submitted annual reports where no serious adverse
events have been noted. Exempt review includes studies
with minimal risk, do not include identifiers, topics are
generally not sensitive, involve non-vulnerable popula-
tions, are exempt from the formal informed-consent re-
quirement, and are exempt from continuing IRB review.
Based on FTM-EC guidelines and the standard review
form, Committee members decide on the review outcomes
as follows: approval (affirmative decision that the submitted
protocol may be conducted as per plan); approval after
amendment (affirmative decision with the requirement that
amendment(s) be incorporated, as recommended); approval
Adams et al. BMC Medical Ethics 2013, 14:33 Page 4 of 11
http://www.biomedcentral.com/1472-6939/14/33with clarification (affirmative decision after satisfactory
clarification(s) have been made), deferment (protocol is not
recommended for approval as submitted, but can be re-
assessed after revision); disapproval (protocol is not
recommended for the reasons specified by the Committee).
In this study, “approval after amendment” and “approval
with clarification” were grouped together as protocols re-
quiring clarification/revision.
The main issues for which clarification or revision
were requested by the FTM-EC, as shown in the meet-
ing reports, were grouped under selected themes, and
subjected to thematic content analysis. The thematic
content is based mainly on the ethical principles/issues
presented on the standard FTM-EC review form, which
accompanies the protocol provided to each FTM-EC
member as a guideline for his/her review. The checklist
on the FTM-EC review form includes issues of scientific
merit, sampling techniques, investigators’ experience,
adequacy of the research facilities, realistic budgeting,
appropriate compensation, study population and vulner-
able populations, type of study, information sheet, and
informed consent process. Particular thematic points of
concern regarding the protocol on the form also include,
for example, project title, objectives, research method-
ology, protection of privacy and confidentiality, major
ethical issues, participant information sheet, informed
consent/assent form, questionnaire/case record form
(including either a printed, optical, or electronic docu-
ment designed to record all of the information required
for the protocol), advertisement/notification about the
study, investigator brochure, and materials transfer ag-
reement (MTA). However, the FTM-EC may add mat-
ters of particular concern to the basic review form. The
content analysis in this study was synthesized from all
issues discussed and recorded during the monthly meet-
ing, including, e.g., research design and study plan, re-
cruitment method, informed-consent process, risk and
benefits of the participants, confidentiality and security
of the study data, and potential societal impact. If one or
more statements addressed an issue related to any of the
major themes, the item was tagged for content analysis.
In the analysis of all documents archived at FTM-EC, 4
faculty members assessed and confirmed the thematic
content. Reflecting the FTM-EC meeting format, con-
sensus was achieved on various issues, and the opinions,
conclusions, and recommendations reached were not
those of the authors alone.
Results
Process of reviewing studies involving
minority populations
During the 3-year study period, 96 clinical and 195 non-
clinical studies were submitted for initial ethical review,
and 43 clinical and 39 non-clinical studies for continuingreview. Among these, 33 clinical and 11 non-clinical re-
search studies involved minority groups in Thailand, in-
cluding cross-border populations, displaced persons,
and/or refugees, and legal and illegal foreign workers in
urban areas of Thailand.
As Table 1 shows, 373 studies were submitted for eth-
ical review; 291 for initial review and 82 for continuing
review. Forty-four (44) studies involved minorities, 23
targeting generic minority populations, and 21 extra-
vulnerable minority populations. Of 291 proposals sub-
mitted for initial review, 77.3% (225/291) underwent
full-board review, 20.3% (59/291) expedited review, and
2.4% (7/291) were exempted from ethical review. To
safeguard the rights, safety, and well-being of all trial
participants, and in compliance with the responsibilities
of IRBs outlined in the ICH Guideline for Good Clinical
Practice [8], all clinical studies, including studies involv-
ing minority groups, submitted for initial review by the
FTM-EC, underwent full-board review, and none was
exempted. On the other hand, of the non-clinical studies
submitted for initial review, only two thirds (66.1%)
underwent full-board review (where the research proto-
col called for the collection of primary data); and about
one third underwent either expedited review (including
studies proposing the use of un-identified leftover speci-
mens with official authorization or analysis of secondary
data) or were exempted (including studies that used
public data or information originally from non-research
program evaluation projects). All 44 studies involving
minority groups underwent full-board review. Regarding
the continuing review of clinical studies, most (74.4%)
underwent expedited review, since no major protocol
amendment, nor amendment with greater than minimal
additional risk, were involved.
Outcomes of the reviews of studies involving
minority populations
Regarding the results of initial review for combined clin-
ical and non-clinical study submissions, 92.1% (268/291)
were referred back to investigators and approved after
satisfactory clarification and/or revision, while 2.7% (8/
291) were deferred, and 2.1% (6/291) not approved. Of
the initial FTM-EC review of clinical studies, none was
awarded simple approval, while most continuing reviews
(62.8%) were. In terms of initial review outcomes for
non-clinical studies, only 6.7% of proposals received sim-
ple approval. A few initial review studies were deferred
(3% of clinical and 2.6% of non-clinical studies) due to
the Ethics Committee’s consensus that the study re-
quired major and critical changes. Similarly, a few ini-
tial studies were not approved (1% of clinical and 0.5%
of non-clinical studies) and some continuing review
studies were not approved (7% of clinical and 2.6%
of non-clinical studies), since the proposed study or its
Table 1 Ethical review outcomes of studies at FTM-EC, 2009-2012
Ethical review process
and outcomes
All studies Studies involving minority groups

















N = 96 N = 43 N = 195 N = 39 N = 19 N = 14 N = 4 N = 7
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Type of review
Full board 96 (100%) 11 (25.6%) 129
(66.1%)
1 (2.6%) 19 (100%) 14 (100%) 4 (100%) 7 (100%)
Expedited 0 32 (74.4%) 59 (30.3%) 38 (97.4%) 0 0 0 0
Exempted 0 0 7 (3.6%) 0 0 0 0 0
Initial review outcome
Simple approval 0 27 (62.8%) 13 (6.7%) 38 (97.4%) 0 0 0 0
Approval after
clarification/revision
92 (96%) 13 (30.2%) 176
(90.2%)
0 17 (89.4%) 12 (86%) 3 (75%) 7 (100%)
Deferment 3 (3%) 0 (0%) 5 (2.6%) 0 1 (5.3%) 1 (7%) 0 0
Non-approval 1 (1%) 3 (7%) 1 (0.5%) 1 (2.6%) 1 (5.3%) 1 (7%) 1 (25%) 0
Notes: 1. “Continuing review” includes studies where an amended protocol was requested and continual annual approval was awarded.
2. “Extra-vulnerable minority” includes pregnant women, fetuses, and neonates.
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ethical principles.
Of the 44 studies involving minority groups undergo-
ing full-board review, none was granted simple approval.
Overall, 88.6% (39/44) were approved after clarification
and/or revision, 4.5% (2/44) were deferred, and 6.8%
(3/44) not approved. Among clinical studies involving
minority populations, 5.3% without extra-vulnerable
groups and 7% with extra-vulnerable populations were
deferred; and the same rates were not approved. One
non-clinical study involving a minority, but without
extra-vulnerable status, was not approved.
Reasons for protocol revision or deferral/non-approval
Proposals that were not granted simple approval under-
went subsequent submissions, incorporating responses
to FTM-EC suggestions. Among the clarifications/revi-
sions requested, research methodology, participant infor-
mation sheet, recruitment (inclusion–exclusion criteria),
and informed consent/assent form, were among the
most frequent issues. Table 2 shows the main issues
of clarification/revision needed for re-submission; the
top three reasons were participant information sheet
(86.4%), informed consent/assent form (86.4%), and re-
search methodology (84.1%). However, for all studies,
research methodology was the issue most frequently re-
quiring clarification/revision (80.7%), followed by par-
ticipant information sheet (62.2%), and recruitment,
specifically inclusion–exclusion criteria (60.1%). The
common matters for which clarification and amend-
ment were requested included inadequate information
on the participant information sheet, the lack of lay
terms to facilitate laypersons’ comprehension, contra-
dictory information in the protocol, lack of approvals
and signatures by authorized personnel, inadequateTable 2 Main issues for which clarification/revision were
requested




N = 44 N = 291
n (%) n (%)
Participant information sheet 38 86.4 181 62.2
Informed consent/assent form 38 86.4 149 51.2
Research methodology 37 84.1 235 80.7
Recruitment (inclusion–exclusion criteria) 32 72.7 175 60.1
Procedures for treatment and care 29 65.9 103 35.4
Risk-benefit considerations 27 61.4 108 37.1
Compensation 26 59.1 76 26.1
Sample size 21 47.7 122 41.9
Minor typographic errors 13 29.5 70 24.0
CRF/Questionnaire/MTA 8 18.2 128 43.9sample size, unclear definitions of inclusion/exclusion
criteria, and poor hypotheses and research questions.
The reasons for deferment and non-approval were also
investigated, as shown in Table 3.
Specific protections are focal at FTM-EC meetings
when studies involve minority groups, particularly those
enrolling under-represented minority populations, such
that culturally sensitive values and the trust of minority
ethnic communities are respected and maintained. The
principles usually recorded in FTM-EC meeting reports
for referral to investigators for clarification/revision in-
clude: (a) ensure no exploitation, coercion, or pressure
to participate among the minority, which is regarded as
a vulnerable population; (b) ensure that the research
methodology does not affect the legal status of the minor-
ity; (c) consider the necessary educational level and com-
petency of the minority research subjects to participate in
the study; (d) understand and consider the ethnicity and
cultural issues of the minority communities being studied;
(e) ensure that the research methodology and instruments
are accepted and understood by minority ethnic partici-
pants; and (f) provide appropriate compensation for the
contributions of the minority participants residing in
under-served and limited-resource environments.
After the FTM-EC had made its decision on a par-
ticular proposal, the reasons for clarification/revision
or deferment/not approval were clearly explained to
the investigators. Selected anonymized excerpts from
correspondence between FTM-EC and investigators are
presented as examples.
On the study objective:
FTM-EC comment - The objectives are not clear. For
example, on page 4/10, the objective of the study is
stated as “To determine the impact of treated XXX
infection”; does this mean that the impact on fetal and
newborn growth is the result of the treatment given to
the mother? If this is the case, can pregnant women
without XXX infection serve as a control group?
Investigator response: As per your suggestion, we have
changed the objective to “To determine the impact of
XXX infection and XXX treatment in pregnancy on fetal
and newborn growth and relate these data to non-
infected mothers and to international growth standards.
On the research methodology:
FTM-EC comment - For the pharmacokinetic study, is
it possible to have the total blood volume taken from
each infant?
Investigator response - After careful discussion with the
hematology and pharmacokinetics labs, we were able
to reduce the round total blood volume from XX ml to
Table 3 Main issues for which studies involving minority groups were deferred/not approved, 2009-2012
Main issues Studies involving
minority groups
All studies
Deferment Non-approval Deferment Non-approval
n = 2 n = 3 n = 8 n = 6
No scientific merit 1 2 1 4
Unsound research methodology 2 3 4 6
Risk-benefit concerns (individual and community) 1 2 3 4
Human rights violations - 1 - 1
No FTM staff involvement and/or not implemented within FTM - - 1 -
Required ethical clearance from elsewhere (Ministry of Public Health), not from FTM-EC - - 1 1
Research conducted and completed before ethical clearance requested - - 1 -
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(exact total reduced from XXX to XXX). Further
reductions do not seem possible without reducing the
scientific value of the study. We hope you will find
this acceptable.
FTM-EC comment - In #14.2 “as many women as
possible will be recruited” is not acceptable. If so, when
will the project end? Sample size calculation is needed.
In fact, you have stated in the explanation form that
XXX participants will be recruited. How did you
determine the number XXX?
Investigator response - We plan to study a total of
XXX women. This sample size will allow us to detect a
difference of X.X% of the endpoint with 80% power
and alpha = 0.025 between the two groups of women.
Allowing 20% drop-out the total number of women to
be recruited into the study is XXX.
On the informed-consent process:
FTM-EC comment – The participant information
sheet (PIS) does not state the risk for patients who do
not have the standard treatment. Please state this
clearly in the PIS.
Investigator response - The PIS has been revised to
clearly explain that XXX is not a standard treatment
and explain the possible risk to patients on page 4 of the
PIS Thai version and page 5 of the PIS English version.
FTM-EC comment – If this project recruits Thais
only, then only a Thai version of the PIS is needed.
If not, please provide the PIS in the appropriate
foreign language.
Investigator response - In our study settings there
might be cross-border patients to be recruited,
therefore, the PIS ICF of the XXX language version willbe provided to FTM-EC soon after the English version
is approved and translated into the XXX language.
Non-approved studies:
FTM-EC rationale - It is not necessary to investigate
such interaction in this vulnerable group. If the
objective is only to investigate the relationship between
this XXX infection and this XXX disease, it can be
done in a normal population.
FTM-EC rationale - This type of XXX infected person
in Thailand does not have such severe XXX deficiency
and thus they are not the targeted population. Even
though the study result may show some associations, it
will not benefit this type of patient. Besides, some
studies in Africa indicated that giving XXX to the
patient was worse rather than better.Discussion
Ethics committees are responsible for reviewing and de-
ciding whether to approve or not approve research pro-
posals, based on ethical principles, as well as scientific
validity. Decisions of ethics committee members are
influenced by the variety of backgrounds, perspectives,
specialties, experiences, and qualifications of its mem-
bers. In a study comparing different ethics committees
[6], it was reported that even when consensus exists within
an ethics committee on the critical issue for approval, in-
terpretations of the decision-making criteria may differ be-
tween committees. Multi-center studies across nations,
regions, or districts, usually require separate applications
to individual committees serving each location. Several of
the studies submitted to FTM-EC were multi-center stud-
ies; they were required to apply if the study involved FTM
personnel or facilities. The decision-making for proposal
approval of the FTM-EC is, however, independent and
based upon local rules and regulations in the location the
study will be performed.
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similar to studies submitted to IRBs in Africa and South
America [13-15], which also reported that 80-90% of pro-
tocols submitted for initial review were referred back to
investigators for clarification and/or revision. As reported
in several other studies regarding the conduct of research
among poor and disadvantaged minorities [4,7,9,10,16],
the closer examination of “vulnerability” to exploitation,
impaired decision-making, or both, are important matters
for the ethics committee. However, it was found in this
study that the rate of requests for protocol revision after
initial review was the same for studies involving minority
groups, regardless of extra-vulnerability, at about 90%.
The reasons for which proposals were not granted simple
approval, and the matters for which clarification and
amendment were requested, were similar to other studies
[11-15,17], and were mostly related to the informed-
consent document and process, and the unclear study de-
sign. The rate of deferment/non-approval among studies
with and without minority populations at FTM-EC (5-7%)
appears not different from ethics committees elsewhere.
These rates are similar to the study in Africa (5% not ap-
proved) and Brazil (1.7% not approved, 7.4% removed/
filed, and 0.5% excluded) [14,15].
Some evidence has been found in the literature [18-20]
that tensions between ethics committees and investigators
are inevitable and unavoidable, especially when a protocol
is deferred or not approved. A universal debate centers on
balancing the IRB’s roles--between its responsibility to
help protect human subjects and the potential to delay or
impede valuable research [17]. However, the FTM-EC has
not experienced major conflicts with investigators over its
years of operation. According to a qualitative study on the
role of the IRB [21], transparency in the review process
will help improve perceptions of IRBs among principal in-
vestigators. In this regard, at the FTM-EC, all multi-
disciplinary aspects of the study are thoroughly discussed
and the reasons for deferral and non-approval are
explained clearly to the investigators. Moreover, a study
on the role of the IRB [21] suggests that tensions could be
reduced by educational efforts and shifts in attitudes,
including IRB responses to investigator complaints, im-
provements in relationships, not acting as draconian “eth-
ics police”, but acting as a facilitator and promoter of
valuable and ethical research involving human subjects.
The recruitment of participants for research studies
is usually challenging, but even more so with vulnerable
minorities. Since studies submitted to FTM-EC involving
minority groups mostly proposed to recruit displaced
populations, cross-border populations, refugees, and legal
and illegal migrant workers, for both clinical and non-
clinical studies, both panels of the ethics committee
focused on vulnerability status. In terms of political sta-
tus, these people possess fewer defined political rightsthan people who can claim citizenship within stable na-
tional frontiers. Besides, refugee camps themselves give
rise to conditions that increase the vulnerability of ref-
uges to potentially abusive research practices. The phys-
ical layout of the camps provides some accessibility and
a population amenable to systemic sampling and data col-
lection [22]. In addition, they are usually economically
impoverished and can be easily influenced to participate
in the research at the prospect of minimal financial gain.
Among other reasons they are attractive to researchers are
the external constraints on movement and location, and
the lack of access to healthcare [23]. Follow-up is also eas-
ier when study subjects are confined to well-defined geo-
graphically isolated areas [7]. However, the “vulnerability”
characteristic that is usually considered to be “incap-
acity or limited capacity of consent” may in fact be a ne-
cessary, but not solely sufficient, condition for defining
vulnerability status [24]. It has been argued that partici-
pation in clinical research provides minority groups
with the opportunity to access state-of-the-art medical
care, normally unavailable to them; however, a study
reviewing the effects of trials [25] suggested that im-
proved outcomes, compared with patients who did not
participate in clinical trials, were the results of multiple
factors, such as medical intervention, treatment regi-
men, and extra follow-up care.
While most requests for clarification/revision among all
studies related to research methodology (80.7%), the top
three for studies involving minority populations were par-
ticipant information sheet (86.4%), informed consent/
assent process (86.4%), and research methodology (84.1%).
The rates of request for clarification/revision for studies
involving minorities were higher than for all studies in all
respects, except for case record form and questionnaire.
This concurs with several studies [7,13,22,26], which noted
that barriers to informed consent arise from social, cul-
tural, economic, language, educational background, and
other factors. In a study of consent among vulnerable pop-
ulations in Mexico [27], about half of patients found the
consent forms difficult to understand; most of the doctors
also confirmed that the forms were incomprehensible to
patients. In a study on the ethical aspects of tissue
research [28], the researchers in many clinical and non-
clinical studies tended to describe recruitment and
informed consent processes very briefly; this could be
resolved by making written detailed guidelines available
for investigators, and training researchers to appreciate
the sensitive ethical issues surrounding minority groups
in research.
At FTM-EC, issues with the recruitment and informed
consent process, and problematic or unclear research
methodology resulted in both clinical and non-clinical
study protocols having to be resubmitted for final ap-
proval. The reasons for which research proposals, with
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approved mainly related to scientific merit and research
methodology; however, about half concerned the balance
of risk-benefit to the individual and community, and vio-
lations of human rights. FTM-EC has also deferred/not
approved some multi-center studies, especially those en-
rolling minority and extra-vulnerable populations, which
involve sponsors from international agencies or phar-
maceutical companies; clear reasons for such review de-
cisions are considered critical. There have also been
instances whereby a particular protocol might be
approved by certain ethics committees, but not by FTM-
EC or by other committees in Thailand. It is thus
important to convey the principle that it is the responsi-
bility of the ethics committees in both sponsor and host
countries (or central and local levels/sites in multi-
center studies) to consider and adhere to scientific and
ethical standards, while maintaining their authority not
to approve research protocols that fail to meet the stan-
dards of the local/host study sites [29]. It is a common
practice to trust ethics committees in host countries to
play the critical role in protocol review, since they are in
a better position to balance the content and context of
the protocol against their better understanding of the
cultural and moral values of the population where the
research is to be conducted [29,30].
On occasion, the FTM-EC recommendation or request
for clarification/revision involved the inclusion of com-
munity engagement in the proposal. Some case studies
of human rights research in low- or middle-income
countries have suggested mechanisms for managing con-
flicts of interest when the research is to be conducted at
a specific study location. An effective method is to en-
courage the use of community engagement and the de-
velopment of standard ethical operating procedures
(SOPs) that will assure the conduct of ethical human re-
search [31]. Studies of the ethical considerations in re-
search being conducted among minority groups suggest
the importance of building foundations for community
involvement, and establishing trust among eligible par-
ticipants [32,33]. Linkages with community leaders are
essential. They can help to generate a positive attitude
towards research activities. Another approach to en-
sure productive community involvement is the estab-
lishment of a community advisory panel. In addition,
key informant insiders can share research information
consistent with the community’s language and cul-
tural practices [33]. Although FTM-EC does not have
a minority representative, the committee contains
members with experience working with minorities in
remote locations (including cross-border areas and
refugee camps).
Moreover, in an attempt to understand minority set-
tings where the research took place and to understandresearchers who work in the areas, the FTM-EC has
usually performed annual study-site visits in selected re-
mote, rural, border areas. As per its SOP, during these
field-site inspections, FTM-EC reviews and examines the
research facilities and documentation, and interviews
minority research subjects and researchers at the study
site. This has facilitated a candid exchange of ideas on
the conduct of ethically sound research. Expectations
and limitations are openly discussed. This has proved an
effective mechanism for creating better understandings
and positive relationships between the ethics committee,
the investigators in the field, the study subjects, and
their communities.
Limitations of the study
The process and outcomes of proposal review in this
study were based on reviews of two ethics committees at
one institute in Thailand; the results may reflect those of
research involving minority populations in similar set-
tings, but may not be generalizable to other settings.
However, the FTM-EC is one of 10 IRBs recognized by
Thailand’s Food and Drug Administration and has been
reviewing more studies involving vulnerable participants
than most other institutes in the country. Its experience
can be instructive for other ethics committees dealing
with vulnerable participants in very limited resources
settings, particularly those with limited education, with
migrants, and cross-border populations. The process
and outcomes of proposal review by FTM-EC are com-
parable to other countries, and may serve as a good ex-
ample of how global standards of research ethics are
successfully applied in less-developed regions of the
world.
Conclusions
Like the outcomes of proposal review in other regions,
most studies reviewed at FTM-EC required one round
of revision and a few were deferred or not approved.
Delays in the approval or non-approval of studies invol-
ving minority populations were mainly due to inad-
equate information on the participant information sheet
and informed consent/assent form, and unclear research
methodology. Other issues on the investigator’s part in-
cluded inadequate level of awareness, knowledge, and
sensitivity among researchers to the vulnerable status of
the study participants, and related ethical implications
and requirements.
To mitigate problems and avoid unfavorable review
outcomes, particularly in studies conducted among vul-
nerable minority populations, it is recommended that in-
vestigators should demonstrate that they have closely
considered the necessity of enrolling such populations as
well as the benefits of their study to both minority par-
ticipants and their communities. Like other ethics
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FTM-EC suggests that investigators should involve par-
ticipating communities and individuals in the early plan-
ning phase, for example, by establishing a community
advisory board, whose membership includes the relevant
minority groups. Several effective mechanisms that have
been demonstrated by the FTM-EC in reducing tensions
between investigators and the ethics committee, including
transparency in the review process and building good rela-
tionships with direct and open communication with the
investigators. In addition, FTM-EC has employed capacity-
building of ethics committee members and researchers to
minimize the need to review problematic issues. Annual
FTM-EC refresher training courses for the research com-
munity have been conducted over the years; however, this
study suggests that it should include sessions to strengthen
the capacity and raise awareness of research staff to engage
minority groups ethically in productive research.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors discussed and agreed upon the thematic content, contributed to
the development and revision of the draft manuscripts, and read and
approved the final version. PA, JK, WW drafted the initial version. KP, SK, WF
(FTM-EC Chairpersons) approved the use of information. WC, CL, SP (Ethics
Committee Secretariat) extracted unlinked study data from the Ethics
Committee archives.
Authors’ information
PA has been Secretary to FTM-EC for the past 19 years, and is Head of the
Office of Research Services. JK is a biostatistics expert, Member of FTM-EC,
Assistant Professor in the Department of Tropical Medicine and Hygiene, and
Director of the Center of Excellence for Biomedical and Public Health
Informatics (BIOPHICS). WW is a current Member and former Member-Secretary
of FTM-EC, and an Associate Professor in the Department of Social and
Environmental Medicine. KP is a Pediatrician, Chair of FTM-EC Panel I, and
Professor in the Department of Tropical Pediatrics. SK is Chair of FTM-EC Panel II,
and Professor in the Department of Microbiology and Immunology. WF is a
current Expert Member in Medical Social Science, former Chair of FTM-EC, and
Head of the Department of Social and Environmental Medicine. WC, CL, and SP,
are assistant secretaries to FTM-EC. All are affiliated with the Faculty of Tropical
Medicine, Mahidol University.
Acknowledgements
The authors would like to thank the FTM-EC Members in both Panels for
their kind support for this study. Special thanks to Mr. Paul Adams of the
Office of Research Services, Faculty of Tropical Medicine, Mahidol University,
for editing the language of the manuscript.
Author details
1Office of Research Services, Faculty of Tropical Medicine, Mahidol University,
Bangkok, Thailand. 2Department of Social and Environmental Medicine,
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
3Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol
University, Bangkok, Thailand. 4Department of Microbiology and
Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok,
Thailand. 5Department of Tropical Hygiene, Faculty of Tropical Medicine,
Mahidol University, Bangkok, Thailand.
Received: 5 March 2013 Accepted: 9 September 2013
Published: 11 September 2013References
1. Department of Health and Human Services: Code of Federal Regulations, Title
45 (Public Welfare), Part 46 (Protection of Human Subjects); 2009.
http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf.
2. Council for International Organizations of Medical Sciences and the World
Health Organization: International Ethical Guidelines for Biomedical Research
Involving Human Subjects, Guideline 13; 2002. http://www.cioms.ch/
frame_guidelines_nov_2002.htm.
3. Bwakura-Dangarembizi M, Musesengwa R, Nathoo KJ, Takaidza P, Mhute T,
Vhembo T: Ethical and legal constraints to children’s participation in
research in Zimbabwe: experiences from the multicenter pediatric HIV
ARROW trial. BMC Med Ethics 2012, 13:17.
4. Grady C: Vulnerability in research: individuals with limited financial and/
or social resources. J Law Med Ethics 2009, 37(1):485–493.
5. Vallely A, Lees S, Shagi C, Kasindi S, Soteli S, Kavit K, Vallely L, McCormack S,
Pool R, Hayes RJ, for the Microbicides Development Programme (MDP):
How informed is consent in vulnerable populations: Experience using a
continuous consent process during the MDP301 vaginal microbicide trial
in Mwanza. Tanzania BMC Med Ethics 2010, 11:10.
6. Goodyear-Smith F, Lobb B, Davies G, Nachson I, Seelau SM: International
variation in ethics committee requirements: comparisons across five
Westernised nations. BMC Med Ethics 2002, 3:2.
7. Lott JP: Module three: vulnerable/special participant populations.
Dev World Bioeth 2005, 5(1):30–54.
8. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH): ICH Harmonised
Tripartite Guideline. Guideline for Good Clinical Practice. E6 (R1). Current Step 4,
Version dated 10 June 1996. http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
9. Greater Glasgow Minority Ethnic Health Research Strategy Group: Ethical
guidelines for conducting research with minority ethnic communities; 2004.
http://www.phru.net/rande/Shared%20Documents/Research%20Guidelines/
Ethical%20Guidelines%20for%20Minority%20Ethnic%20Research.pdf.
10. Connolly P: Ethical principles for researching vulnerable groups; 2003. http://
www.ed.ac.uk/polopoly_fs/1.71235!/fileManager/EthicsPr-Vulnerable.pdf.
11. Bueno M, Brevidelli MM, Cocarelli T, Santos GM, Ferraz MA, Mion Jr D:
Reasons for resubmission of research projects to the research ethics
committee of a university hospital in São Paulo, Brazil. Clinics (Sao Paulo)
2009, 64:831–836.
12. Keinonen T, Nieminen S, Saano V, Ylitalo P: Acceptability and profile of the
clinical drug trials underway in Finnish university hospitals in the 1990s:
applications reviewed by ethics committees. Methods Find Exp Clin
Pharmacol 2001, 23(7):415–423.
13. Dada MA, Moorad R: A review of South African Research Ethics
Committee. Issues Med Ethics 2001, 9(2):58–59.
14. Novaes MRG, Guilhem D, Lolas F: Ethical conduct in research involving
human beings in Brazil: diagnosis of research ethics committee. Arq Med
2009, 23(4):145–150.
15. Eyelade OR, Ajuwon AJ, Adebamowo CA: An appraisal of the process of
protocol review by an ethics review committee in a tertiary institution in
Ibadan. Afr J Med Med Sci 2011, 40(2):163–169.
16. Denny C, Grady C: Clinical research with economically disadvantaged
populations. J Med Ethics 2007, 33:382–385.
17. Angell E, Dixon-Woods M: Do research ethics committees identify
process errors in applications for ethical approval? J Med Ethics 2009,
35:130–132.
18. Burris S, Moss K: U.S. health researchers review their ethics review boards:
a qualitative study. J Empir Res Hum Res Ethics 2006, 1(2):39–58.
19. Keith-Spiegel P, Koocher GP, Tabachnick B: What scientists want from
their research ethics committees. J Empir Res Hum Res Ethics 2006,
1(1):67–82.
20. Koerner AF: Communication scholars’ communication and relationship
with their IRBs. J Appl Commun Res 1995, 33(3):231–241.
21. Klitzman R: The ethics police?: IRBs’ views concerning their power.
PLoS One 2011, 6(12):e28773.
22. Leaning J: Ethics of research in refugee populations. Lancet 2001,
357:1432–1433.
23. Wendler D, Grady C: Ethical issues in research with special populations.
http://www.bioethics.nih.gov/research/special.pdf.
24. Weisser-Lohmann E: Ethical aspects of vulnerability in research.
Poiesis Prax 2012, 9:157–162.
Adams et al. BMC Medical Ethics 2013, 14:33 Page 11 of 11
http://www.biomedcentral.com/1472-6939/14/3325. Braunholtz DA, Edwards SJ, Lilford RJ: Are randomized clinical trials good
for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol
2001, 54:217–224.
26. Pace C, Emanuel EJ, Chuenyam T, Duncombe C, Bebchuk JD, Wendler D,
et al: The quality of informed consent in a clinical research study in
Thailand. IRB 2005, 27(1):9–17.
27. Verastegui EL: Consenting of vulnerable: the informed consent procedure
in advanced cancer patients in Mexico. BMC Med Ethics 2006, 7:13.
28. Halkoaho A, Pietilä A-M, Vesalainen M, Vähäkangas K: Ethical aspects in
tissue research: thematic analysis of ethical statements to the research
ethics committee. BMC Med Ethics 2012, 13:20.
29. Diekema DS: Conducting ethical research in pediatrics: a brief historical
overview and review of pediatric regulations. J Pediatr 2006, 149:S3–S11.
30. Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical?
JAMA 2000, 283(20):2701–2711.
31. Amon JJ, Baral SD, Beyrer C, Kass N: Human rights research and ethics
review: protecting individuals or protecting the state? PLoS Med 2012,
9(10):e1001325.
32. Arzubiaga AE, Artiles AJ, King KA, Harris-Murri N: Beyond research on
cultural minorities: challenges and implications of research as situated
cultural practice. Except Child 2008, 74(3):309–327.
33. Diaz V: Encouraging participation of minorities in research studies.
Ann Fam Med 2012, 10(4):372–373.
doi:10.1186/1472-6939-14-33
Cite this article as: Adams et al.: Ethical issues in research involving
minority populations: the process and outcomes of protocol review by the
Ethics Committee of the Faculty of Tropical Medicine, Mahidol University,
Thailand. BMC Medical Ethics 2013 14:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
